UNCY vs. ACB, KRRO, PRME, NVCT, ACIU, ZYBT, BTMD, ELDN, YMAB, and LFVN
Should you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include Aurora Cannabis (ACB), Korro Bio (KRRO), Prime Medicine (PRME), Nuvectis Pharma (NVCT), AC Immune (ACIU), Zhengye Biotechnology (ZYBT), biote (BTMD), Eledon Pharmaceuticals (ELDN), Y-mAbs Therapeutics (YMAB), and LifeVantage (LFVN). These companies are all part of the "pharmaceutical products" industry.
Unicycive Therapeutics vs.
Unicycive Therapeutics (NASDAQ:UNCY) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.
Unicycive Therapeutics currently has a consensus target price of $5.33, indicating a potential upside of 746.56%. Given Unicycive Therapeutics' higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than Aurora Cannabis.
Unicycive Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500.
Aurora Cannabis has a net margin of 0.42% compared to Unicycive Therapeutics' net margin of 0.00%. Aurora Cannabis' return on equity of 0.59% beat Unicycive Therapeutics' return on equity.
Unicycive Therapeutics has higher earnings, but lower revenue than Aurora Cannabis. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 24.1% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Aurora Cannabis received 352 more outperform votes than Unicycive Therapeutics when rated by MarketBeat users. However, 76.19% of users gave Unicycive Therapeutics an outperform vote while only 59.63% of users gave Aurora Cannabis an outperform vote.
In the previous week, Aurora Cannabis had 4 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 6 mentions for Aurora Cannabis and 2 mentions for Unicycive Therapeutics. Aurora Cannabis' average media sentiment score of 0.80 beat Unicycive Therapeutics' score of 0.62 indicating that Aurora Cannabis is being referred to more favorably in the news media.
Summary
Aurora Cannabis beats Unicycive Therapeutics on 12 of the 19 factors compared between the two stocks.
Get Unicycive Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Unicycive Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:UNCY) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy UNCY Stock Free UNCY Stock Alerts